pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 14·1 min read
save

Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question

May 14, 2026·read at onclive ↗

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

read at onclive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
HER22ImmunologyOncology

related stories

  • May 7Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROConclive
  • May 7Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.onclive
  • May 7ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studiesonclive
  • May 7Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026onclive
  • May 7Reigniting Your Curiosity During Fellowshiponclive